Charles Peterfy, MD, PhD is an American Board certified radiologist with fellowship training from University of California San Francisco (UCSF) and a PhD in Pharmacology and Therapeutics from McGill University. He was attending radiologist at UCSF for seven years where he also served as Director of Arthritis and MRI Research for the Osteoporosis and Arthritis Research Group, which conducted numerous clinical trials and epidemiological studies through the university.

In 1998, Dr. Peterfy co-founded Synarc Inc, which became the largest imaging core lab in the world by 2000. He served as its Chief Scientific Officer and Executive Vice President for 11 years. As Synarc grew, it expanded beyond imaging to include a broad range of services for clinical research, and in 2021 it became Clario, a general CRO.

In 2009, Dr. Peterfy left Synarc, and formed Spire Sciences, to bring the focus back to imaging, particularly excellence in imaging for diseases that needed special expertise, and where he felt Spire could make a significant positive impact and out-perform other imaging core labs.

Spire Sciences succeeded in those objectives, as evidenced by having been trusted to read the majority of clinical trials worldwide that used imaging in those key therapeutic areas for the past 15 years, having developed many of the outcome measures and imaging techniques that have become the standards for clinical trials in those areas.

Dr. Peterfy was the first to develop and validate a technique for quantifying articular cartilage in the knee and hand using MRI 30 years ago. He developed the fixed-flexion X-ray technique and positioning frame (SynaFlexer and the newer Fixed Flexion Frame), which has been the most widely used method for radiographically evaluating the knee in osteoarthritis for more than 25 years. He also developed fixed-location joint-space width measurement for monitoring osteoarthritis progression more sensitively than possible with conventional minimum joint-space width measurement. He also developed the Whole Organ MRI Scoring method, WORMS, which has been the most widely used multi-feature MRI assessment method for evaluating osteoarthritis in epidemiological studies and clinical trials for over 25 years.

In 2002, Dr. Peterfy in conjunction with the OMERACT (Outcome Measures in Rheumatology Clinical Trials) MRI Working Group, which he co-chairs, developed the RAMRIS (Rheumatoid Arthritis MRI Scoring) method for evaluating rheumatoid arthritis in clinical trials. He also co-developed PsAMRIS (Psoriatic Arthritis MRI Scoring) and HOAMRIS (Hand Osteoarthritis MRI Scoring). These methods have been the most widely used for evaluating inflammatory arthritis, and are currently the standards for clinical trials using MRI. Dr. Peterfy also developed CARLOS (Cartilage Loss Score), the most commonly used method for monitoring cartilage loss in rheumatoid arthritis with MRI, and he invented the Syn-X-RA and X-frame positioning devices for error-free radiography of the hand and foot in arthritis, along with the Syn-M-RA and M-frame devices for reproducible MRI of the hand and wrist in arthritis trials.

He chaired the Imaging Working Group of the NIH Osteoarthritis Initiative, one of the first public-private partnerships between NIH and the pharmaceutical industry and the largest natural history study of osteoarthritis ever conducted, and he supervised the collection and central quality control of the images for that historic study, which are available to the public worldwide for clinical research.

In 2006, he co-founded the International Society for Imaging in Rheumatology, ISEMIR, a non-profit organization aimed at advancing imaging in rheumatology through research and education, and he served as its President until it was shut down in 2021 in the wake of the Covid pandemic.

He also served on the Board of Directors of the Intersocietal Accreditation Commission (IAC) from 2016 to 2021, establishing standards and guidelines for accrediting imaging facilities throughout the US.

In Oncology, Dr. Peterfy developed several outcome measures specially designed for Tenosynovial Giant Cell Tumor (TGCT), arguably the most difficult tumor of all to measure longitudinally in clinical trials because of its diffuse nature, highly irregular shape, ill-defined margins, local invasiveness and asymmetrical growth. These measures include modified-RECIST for TGCT, the Tumor Volume Score (TVS) and the multi-feature Tissue Damage Scoring method (TDS), which out-performed RECIST 1.1 and expand on it in clinically meaningful ways. Using these methods, Spire Sciences has read the images for most if not all trials of TGCT globally over the past 11 years, for which effective therapies, sometimes even curative, are now available in the clinic, when before the options available to these patients were extremely limited.

Dr. Peterfy has authored two textbooks and over 200 scientific articles and book chapters, and participated in numerous standardization committees, scientific advisory boards and expert panels for advancing imaging in clinical trials.

Caroline Reinhold, MD, MSc is Vice-President of Oncology at Spire Sciences. Dr. Reinhold is an internationally recognized leader in oncological and gynecological imaging, and has been developing, validating, and implementing oncological imaging techniques, and classification and reporting imaging systems used world-wide for over 25 years. She has extensive experience in leading large multicenter imaging clinical trials both for industry and academia. She is also an international recognized leader in the field of artificial intelligence with numerous peer-reviewed publications and has lectured on the accuracy, ethics, governance, and implementation of AI solutions in medical imaging.

Dr. Reinhold is an American board-certified radiologist with fellowship training from Yale University and an MSc in Epidemiology and Biostatistics from McGill University. She is Associate Chair of Research for the Department of Radiology at McGill University, co-founder and director of the Augmented Imaging Precision Health Laboratory (AIPHL) at the Research Institute of the McGill University Health Center, prior interim Chair and Director of the Clinical Trials Imaging Unit at the Center of Innovative Medicine at the Research Institute of the McGill University Health Center. She is currently also co-chair of the Ovarian-Adnexal Reporting & Data System (O-RADS) of the American College of Radiology, and is the MRI lead for the International Federation of Gynecology and Obstetrics (FIGO) Menstrual Disorders Adenomyosis subcommittee.

In 1999, Dr. Reinhold joined Synarc Inc. (currently Clario Inc.), which was at the time the largest imaging core lab in the world, and she served as its Medical Director of Oncology for 10 years. In that capacity she developed Synarc's oncology service line. In 2010, Dr. Reinhold returned to academia and clinical radiology, but consulted and read clinical trials images for Spire Sciences. In 2024, she became VP of Oncology for Spire Sciences to extend its superior reading processes and systems to a broader range of oncological indications.

Dr. Reinhold has authored 4 textbooks and over 350 scientific articles and book chapters, and participated in numerous standardization committees, scientific advisory boards and expert panels advancing imaging for clinical trials in oncology and gynecology.

Peter Countryman, PhD is Chief Operating Officer at Spire Sciences. Dr. Countryman received his PhD in Physics from Stanford University and worked for several years in the field of PET imaging, making use of his knowledge of nuclear medicine instrumentation and his scientific programming skills to improve the image quality of a sodium-iodide based PET system, and to develop an image reconstruction technique for PET with limited projections.

In 1995, he joined the faculty of the University of California San Francisco (UCSF) and oversaw the development of viewing software for clinical trials conducted by the Osteoporosis and Arthritis Research Group (OARG).

He joined Synarc (now Clario) at its founding in 1998 as Senior Software Architect, and quickly advanced to Product Manager, serving as liaison between the scientific staff and the engineering department. He played a major part in the design and development of Synarc's medical image database/archive system (IMDA), and led the development of the systems supporting the NIH Osteoarthritis Initiative (OAI). In 2009, Dr. Countryman joined Spire Sciences at its founding, and served as Senior Scientist and Scientific Director before becoming Chief Operating Officer. He developed the computing infrastructure at Spire, including Spire's PACS (Picture Archival and Communications System), relational databases and software for reading images and producing reports. Spire Sciences functions in a virtual environment, with all servers hosted in the cloud, and all users accessing the data through a virtual private network.

Dr. Countryman is also expert in international regulations and security with respect to Clinical Trial Imaging.